Document is current

Article History

Received: 14 March 2025

Accepted: 16 October 2025

First Online: 27 November 2025

Declarations

:

: The study was reviewed by the Western Institutional Review Board-Copernicus Group (WCG) institutional review board and received an exempt status determination on March 30th, 2022. All participants provided informed consent to participate in the study.

: Not applicable.

: SNC and ZH are employees of Roche Molecular Systems, Inc. and hold equity, including stocks and stock options, in Roche. AJA is an employee of Roche Diagnostics Limited and holds stock options. VN was employed by Roche Diagnostics Canada at the time the study was conducted and is now employed by Abbott Diabetes Care. MM has received research funding from Roche and has also received funding as a speaker from Takeda Pharmaceuticals. Further, MM serves as an advisor to Signal 1 and Mutuo Health Solutions. RB: Declarations (last 36 months): Research grants: Siemens Healthineers. Consultancy: Roche Diagnostics, Siemens Healthineers, LumiraDx, Prolight Diagnostics. Educational grants: PeerVoice, EMCREG International. Travel to present at conference: Astra Zeneca. LK: Conflict: Consultant: Pfizer Pharmaceuticals. Consultant: Roche Diagnostics. EE, CD, GT, and KW are employees of Acaster Lloyd Consulting Ltd and may hold stock or stock options in the company. Acaster Lloyd Consulting Ltd were commissioned by Roche to conduct the research summarized in this article.